<DOC>
	<DOCNO>NCT02908100</DOCNO>
	<brief_summary>This multicenter , Phase II , randomize , double-blind , placebo-controlled , parallel-group , dose-ranging study evaluate safety efficacy GDC-0853 combination standard care therapy participant moderate severe active systemic lupus erythematosus ( SLE ) .</brief_summary>
	<brief_title>A Study Safety Efficacy GDC-0853 Participants With Moderate Severe Active Systemic Lupus Erythematosus</brief_title>
	<detailed_description />
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<criteria>American College Rheumatology ( ACR ) Systemic Lupus International Collaborating Clinics ( SLICC ) criterion time prior screening At least one serologic marker SLE screening follow : positive antinuclear antibody ( ANA ) test immunofluorescent assay titer &gt; /= 1:80 ; positive antidoublestranded DNA ( antidsDNA ) antibodies ; positive antiSmith antibody At screen Day 1 , moderate severe active SLE , define meeting following : Safety Estrogen Lupus Erythematosus National AssessmentSLE Disease Activity Index ( SELENASLEDAI ) score &gt; /=6 ( clinical SELENASLEDAI score &gt; /= 4.0 ) ; Physician 's global assessment &gt; /= 1.0 ( 3 ) ; currently receive least one standard oral treatment SLE Participants must willing avoid pregnancy If oral corticosteroid ( OCS ) , dose must &lt; /= 40 mg/day prednisone ( equivalent ) Stable dos antimalarial immunosuppressive therapy Neuropsychiatric central nervous system lupus manifestation Estimated glomerularfiltration rate &lt; 30 millileter per minute ( mL/min ) chronic renal replacement therapy History receive solid organ transplant Evidence active , latent , inadequately treated infection Mycobacterium tuberculosis ( TB ) History cancer , include hematological malignancy solid tumor , within 10 year screen Need systemic anticoagulation warfarin , oral injectable anticoagulant , antiplatelet agent Evidence chronic and/or active hepatitis B C</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>